Literature DB >> 22077546

Management of low (favourable)-risk prostate cancer.

H Ballentine Carter1.   

Abstract

What's known on the subject? and What does the study add? Most men who are diagnosed with favourable-risk prostate cancer undergo some form of active intervention, despite evidence that treatment will not improve health outcomes for many. The decision to undergo treatment after diagnosis is, in part, related to the inability to precisely determine the long-term risk of harm without treatment. Nevertheless, physicians should consider patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments, before recommending a management option. This is especially important for older men, given the high level of evidence that those with low-risk disease are unlikely to accrue any benefit from curative intervention. What is known on the subject: Over treatment of favourable-risk prostate cancer is common, especially among older men. What does the study add: A review of the natural history of favourable-risk prostate cancer in the context of choices for management of the disease. • The management of favourable-risk prostate cancer is controversial, and in the absence of controlled trials to inform best practice, choices are driven by personal beliefs with resultant wide variation in practice patterns. • Men with favourable-risk prostate cancer diagnosed today often undergo treatments that will not improve overall health outcomes. • A shared-decision approach for selecting optimal management of favourable-risk disease should account for patient age, overall health, and preferences for living with cancer and the potential side effects of curative treatments.
© 2011 THE AUTHOR. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22077546      PMCID: PMC4086468          DOI: 10.1111/j.1464-410X.2010.10489.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  65 in total

Review 1.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

2.  Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.

Authors:  Yonah Krakowsky; Andrew Loblaw; Laurence Klotz
Journal:  J Urol       Date:  2010-05-15       Impact factor: 7.450

3.  NCCN clinical practice guidelines in oncology: prostate cancer.

Authors:  James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

4.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Authors:  Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja
Journal:  Lancet Oncol       Date:  2010-07-02       Impact factor: 41.316

5.  The prostate cancer treatment bazaar: comment on "Physician visits prior to treatment for clinically localized prostate cancer".

Authors:  Michael J Barry
Journal:  Arch Intern Med       Date:  2010-03-08

6.  Risk stratification of men choosing surveillance for low risk prostate cancer.

Authors:  Kenneth S Tseng; Patricia Landis; Jonathan I Epstein; Bruce J Trock; H Ballentine Carter
Journal:  J Urol       Date:  2010-03-20       Impact factor: 7.450

7.  Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml.

Authors:  Yu-Hsuan Shao; Peter C Albertsen; Calpurnyia B Roberts; Yong Lin; Amit R Mehta; Mark N Stein; Robert S DiPaola; Grace L Lu-Yao
Journal:  Arch Intern Med       Date:  2010-07-26

8.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

9.  Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.

Authors:  Pär Stattin; Erik Holmberg; Jan-Erik Johansson; Lars Holmberg; Jan Adolfsson; Jonas Hugosson
Journal:  J Natl Cancer Inst       Date:  2010-06-18       Impact factor: 13.506

10.  Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?

Authors:  Roderick C N van den Bergh; Ewout W Steyerberg; Ali Khatami; Gunnar Aus; Carl Gustaf Pihl; Tineke Wolters; Pim J van Leeuwen; Monique J Roobol; Fritz H Schröder; Jonas Hugosson
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

View more
  9 in total

1.  Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome.

Authors:  Jouhyun Jeon; Ekaterina Olkhov-Mitsel; Honglei Xie; Cindy Q Yao; Fang Zhao; Sahar Jahangiri; Carmelle Cuizon; Seville Scarcello; Renu Jeyapala; John D Watson; Michael Fraser; Jessica Ray; Kristina Commisso; Andrew Loblaw; Neil E Fleshner; Robert G Bristow; Michelle Downes; Danny Vesprini; Stanley Liu; Bharati Bapat; Paul C Boutros
Journal:  J Natl Cancer Inst       Date:  2020-03-01       Impact factor: 13.506

2.  Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  Hepatol Int       Date:  2012-10-26       Impact factor: 6.047

Review 3.  Active surveillance for low-risk prostate cancer - in pursuit of a standardized protocol.

Authors:  Roman Sosnowski; Hubert Kamecki; Siamak Daneshmand; Jan K Rudzinski; Marc A Bjurlin; Francesco Giganti; Monique J Roobol; Laurence Klotz
Journal:  Cent European J Urol       Date:  2020-06-25

4.  Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.

Authors:  Christopher Whelan; Mark Kawachi; David D Smith; Jennifer Linehan; Gail Babilonia; Rosa Mejia; Timothy Wilson; Steven S Smith
Journal:  J Urol       Date:  2013-05-10       Impact factor: 7.450

Review 5.  STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy.

Authors:  Melanie Spitzner; Reinhard Ebner; Hendrik A Wolff; B Michael Ghadimi; Jürgen Wienands; Marian Grade
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

6.  The Mind: Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind?

Authors:  Leonardo de Oliveira Reis; H Ballentine Carter
Journal:  Int Braz J Urol       Date:  2015 Jan-Feb       Impact factor: 1.541

7.  Comparison of bi- and multiparametric magnetic resonance imaging to select men for active surveillance.

Authors:  Karen-Cecilie D Thestrup; Vibeke Løgager; Lars Boesen; Henrik S Thomsen
Journal:  Acta Radiol Open       Date:  2019-07-31

8.  Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer.

Authors:  Gillian O'Hurley; Christer Busch; Linn Fagerberg; Björn M Hallström; Charlotte Stadler; Anna Tolf; Emma Lundberg; Jochen M Schwenk; Karin Jirström; Anders Bjartell; William M Gallagher; Mathias Uhlén; Fredrik Pontén
Journal:  PLoS One       Date:  2015-08-03       Impact factor: 3.240

9.  Evaluation of prediction models for the staging of prostate cancer.

Authors:  Susie Boyce; Yue Fan; Ronald William Watson; Thomas Brendan Murphy
Journal:  BMC Med Inform Decis Mak       Date:  2013-11-15       Impact factor: 2.796

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.